X T L Biopharmaceuticals Ltd (XTLB) FinancialsXTLBX T L Biopharmaceuticals Ltd

X T L Biopharmaceuticals Ltd (XTLB) generates its revenue primarily from Operating Segment / Medical Devices, which accounts for -205.2% of total sales, equivalent to $-589.00K. Understanding this concentration is critical for investors evaluating how XTLB navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, X T L Biopharmaceuticals Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -29.30%, provide a clear picture of how effectively XTLB converts its operational activities into shareholder value.

In the context of the broader market, XTLB competes directly with industry leaders such as ARAY and RMTI. With a market capitalization of $6.84M, it holds a significant position in the sector. When comparing efficiency, XTLB's gross margin of N/A stands against ARAY's 34.76% and RMTI's 18.24%. Such benchmarking helps identify whether X T L Biopharmaceuticals Ltd is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 28.40% in Q3 2024 but has been operating at a net loss, with a net income of -553,000 USD in the same quarter. The forward P/E ratio is currently at 0, indicating no earnings expectations in the near term.